Dermatol. praxi. 2008;2(1):6-9

The options of hormonal treatment of acne

doc. MUDr. Jarmila Rulcová CSc
Dermatovenerologická klinika, FN Brno

Acne vulgaris accompanied by seborrhea and in some cases also by other symptoms of androgen secretion excess belongs to the most frequent diseases of teen age. The treatment with combined contraceptives brings very good results in spite of the fact that women suffering from acne, seborhoic dermatitis and mild hirsutism have in most cases normal plasmatic levels of androgens. Especially combinations with antiangrogens are causal therapy, because they block androgenic influence on receptor level, decrease the activity of 5-alfa-reductase and suppress hypothalamopituitary function. Cyproteronacetate shows the strongest antiangrogenic activity, followed by chlormadinonacetate, dienogest and drospirenone.

Keywords: acne, androgens, antiandrogens, combined hormonal contraception

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rulcová J. The options of hormonal treatment of acne. Dermatol. praxi. 2008;2(1):6-9.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arenberger P. Akné - hádanka pro dermatovenerologa, pediatra, imunologa, psychologa, kosmetičku... Akne Report, 2003; 2: 2.
    2. Cibula D. Hormonální kontracepce. In: Cibula D, Henzl MR, Živný J et al. Základy gynekologické endokrinologie. Praha: Grada Publishing, 2000: 201-226.
    3. Cibula D. Přípravek kombinované hormonální kontracepce s novým gestagenem - dienogestem. Moderní gynekologie a porodnictví, 2002; 11, č. 1. Suppl. A: 107-108.
    4. Čepický P. Úvod do antikoncepce pro lékaře negynekology. Praha: LEVRET s.r.o., 2002: 92 s.
    5. Gollnick H, Cunfliffe W. Management of Acne. A Report From a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol, 2003; 49: 1-38. Go to original source... Go to PubMed...
    6. Jansen T, Dissemond J, Grabbe S. Aktuelle Vorstellungen zur Entstehung von Komedonen (Komedogenesse) und Implikationen fur eine Pathogenese-orientierte Aknetherapie. Aktual Dermat, 2005; 10: 491-494. Go to original source...
    7. Leyden J, Shalita A, Hordinsky M et al. Efficacy of a low-dose contraceptive containing 20 ?g of ethinyl estradiol and 100 ?g of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial. J Am Acad Dermatol. 2002; 47: 399-409. Go to original source... Go to PubMed...
    8. Muhn P, Krattenmacher R, Beier S et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Contraception 1995; 51: 99-110. Go to original source... Go to PubMed...
    9. Nürnberger F. The Therapy of Acne vulgaris in Women. Walter de Gruyter et Co., Berlin - New York 1990. Neumann F. Fundamentals of antiandrogen therapy of androgenic skin disorders: s. 9-29.
    10. Paseka J, Unzeitig V, Hořejší V et al. Klinická studie s třífázovým antikoncepčním přípravkem (norgestimát 180/215/250 ?g + ethinylestradiol 35 ?g) v populaci českých žen. Čes. Gynek. 1999; 4: 246-254.
    11. Plewig G, Kligman AM. Acne and Rosacea. 3rd Completely Revised and Enlarged Edition. Springer-Verlag Berlin Heidelberg: New York, 2000: 744 s. Go to original source...
    12. Rabe T, Kowald A et al. Inhibition of skin 5-alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000; 14(4): 223-230. Go to original source... Go to PubMed...
    13. Raudrant D, Rabe T. Progestogens with Antiandrogenic Properties. Drugs 2003; 63(5): 463-492. Go to original source... Go to PubMed...
    14. Rulcová J. Celkově aplikovaná léčba. Referátorový výběr z Dermatovenerologie, Acne vulgaris, Speciál, II-2004: 16-24.
    15. Schramm G, Steffens D. Contraceptive Efficacy and Tolerability of Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mg (Belara(R)). Results of a Post-Marketing Surveillance Study. Clin Drug Invest 2002; 22, (4): 221-230. Go to original source...
    16. Spona J, Aydinlik S. Hirsutism and Endocrine Dermatological Problems. The Parthenon Publishing Group Ltd, 1989. Flamigni C, Venturoli S, Fabbri R. Long - term management of hirsute patients with cyproterone acetate: s. 29-37.
    17. Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation and therapies. (Review). Seminars in Cutaneous Medicine et Surgery 2001; 20, no. 3: 144-153. Go to original source... Go to PubMed...
    18. Thiboutot DM, Chen W. Update and future of hormonal therapy in acne. Dermatology, 2003; 206(1): 57-67. Go to original source... Go to PubMed...
    19. Vohradníková O. Terapie akné dospělých žen. Trendy v medicíně 2000; 2(4): 27-28.
    20. Zelenková H. Možnosti ovplyvnenia acne vulgaris prípravkom a obsahom desogestrelu a ethinylestradiolu. Derma 3. tisícročia 2003; 3: 13-16.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.